Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status

@article{Banday2020PotentialRT,
  title={Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status},
  author={Abid H. Banday and Shameem Ahmad Shameem and Sheikh Ajaz},
  journal={SLAS Discovery},
  year={2020},
  volume={25},
  pages={1097 - 1107}
}
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019. Since then, the virus has stretched its grip to almost all the countries in the world, affecting millions of people and causing enormous casualties. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2019. As of June 12, 2020, almost 7.30 million people have already been infected globally, with 413,000 reported casualties. In the United States… Expand
Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic
TLDR
The ongoing clinical trial landscape of the COVID-19 as well as repurposed vaccines, an insight into the current status of the available antigenic epitopes for SARS-CoV-2 and different types of vaccine platforms of CO VID-19 vaccines has been discussed. Expand
Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
TLDR
The current review highlights the different approaches and technologies used around the world for the design and development of the vaccines and also focuses on the recent status of the SARS-CoV-2 vaccine candidates under development by various institutions to combat the world threat of COVID-19 pandemic. Expand

References

SHOWING 1-10 OF 66 REFERENCES
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
TLDR
This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro. Expand
SARS-CoV-2 Vaccines: Status Report
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discussExpand
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients
TLDR
The data from this small-sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients, and suggest that repurposing danobrevir for COVID-19 is a promising therapeutic option. Expand
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
TLDR
These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use. Expand
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
TLDR
From in vivo studies using several animal models, the pyrazinecarboxamide derivatives were found to be effective in protecting animals from death, reducing viral burden, and limiting disease manifestations, even when treatment was initiated after virus inoculation. Expand
Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
TLDR
This review highlights the development of macrocyclic anti-HCV NS3/4A protease inhibitors, as well as clinically important inhibitors developed from linear peptides, discovered during the last 12 years from all sources, including laboratory synthetic methods, virtual screening and structure-based molecular docking studies. Expand
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
TLDR
In vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients are evaluated. Expand
Compassionate Use of Remdesivir for Patients with Severe Covid-19
TLDR
In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients, and Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesavir therapy. Expand
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
TLDR
The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route and work that may provide a basis for development of anticoronaviral drugs. Expand
The mechanism of resistance to favipiravir in influenza
TLDR
It is demonstrated that a mutation in a conserved region of the viral RNA polymerase confers resistance to favipiravir in vitro and in cell culture, and this mutation has a cost to viral fitness, but fitness can be restored by a compensatory mutation in the polymerase. Expand
...
1
2
3
4
5
...